Minneapolis-based Diamedica Therapeutics Inc. shares (NASDAQ:DMAC) closed Thursday at $4.94, up $1.12, or 29%, after trading as high as $5.93 as Wall Street made known its appreciation of positive interim data from the phase Ib study from 28 evaluable participants with moderate and severe chronic kidney disease (CKD). Read More
Zymeworks Inc. has filed to raise $175 million in a public offering that President and CEO Ali Tehrani told BioWorld will fund his team's "very ambitious plans" for two pivotal phase II/III trials for lead candidate ZW-25 in 2020 and a ramping-up of their study of a second candidate, ZW-49. "We did have the money," but with the additional funds, preparations will move much faster, he said. Read More
It's easy to imagine a U.S. regulatory system that advances the latest cures and therapies and immediately reimburses for new life-saving technologies. But when the regulatory status quo often delays and even stifles innovation, researchers, patients, and drug and device companies find it difficult, try as they might, to realize what so easily can be imagined. Read More
HONG KONG – Astrazeneca plc said it will invest $630 million over the next five years in South Korea's health care industry, marking the largest-ever investment by a foreign pharma company in Korea. Read More
LONDON – The World Health Organization has issued a plea for donors to close a $54 million gap in funding for its Ebola epidemic response in the Democratic Republic of Congo (DRC), after the disease spread to neighboring Uganda and a fresh wave of unrest prompted a mass movement of people in one of the affected areas of DRC. Read More
Seven and Eight Biopharmaceuticals Inc. has signed a clinical research collaboration agreement with Roche Holding AG to explore the combination of BDB-001, an immune modulator targeting Toll-like receptors (TLR) 7 and 8, and atezolizumab, a monoclonal antibody against checkpoint target PD-L1, in treating solid tumors. Read More
Confo Therapeutics NV, of Ghent, Belgium, said it has been awarded a €1.7 million (US$1.9 million) two-year grant from Flanders Innovation & Entrepreneurship that will support one of its preclinical programs, targeting a neurological orphan indication. Read More
Tetra Bio-Pharma Inc., of Ottawa, a cannabinoid-focused company, said it filed a preliminary short form prospectus for a proposed offering of units for minimum gross proceeds of CA$3.5 million (US$2.7 million) and maximum gross proceeds of CA$7 million. Read More
